Article Information
History
- May 5, 2022.
Article Versions
- You are currently viewing Version 1 of this article (May 5, 2022 - 15:12).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Adam Abdullahi1,2,3,*,
- David Oladele4,*,
- Steven A. Kemp1,2,*,
- James Ayorinde4,
- Abideen Salako4,
- Fehintola Ige4,
- Douglas Fink5,6,
- Chika Onwuamah4,
- Qosim Osuolale4,
- Rufai Abubakar4,
- Azuka Okuruawe4,
- Gideon Liboro4,
- Oluwatosin Odubela4,
- Gregory Ohihoin4,
- Oliver Ezechi4,
- Olagoke Usman7,
- Sunfay Mogaji7,
- Adedamola Dada7,
- Soraya Ebrahimi8,
- Lourdes Ceron Gutierrez8,
- Sani H. Aliyu8,
- Rainer Doffinger8,
- Rosemary Audu4,
- Richard Adegbola4,
- Petra Mlcochova1,2,$,
- Babatunde Lawal Solako4,$,# and
- Ravindra K. Gupta1,2,9,$,#
- 1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
- 2Department of Medicine, University of Cambridge, Cambridge, UK
- 3Institute of Human Virology, Abuja, Nigeria
- 4Nigeria Institute of Medical Research (NIMR), Yaba, Lagos
- 5Faculty of Infection and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
- 6Department of Infection and Immunity, University College London, London, UK
- 7Federal Medical Centre, Ebutte Metta, Lagos
- 8Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
- 9Africa Health Research Institute, Durban, South Africa
- ↵$Joint corresponding authors; email: rkg20{at}cam.ac.uk
- ↵#Correspondence to:
Ravindra K. Gupta, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK, rkg20{at}cam.ac.uk or Babatunde Lawal Solako, Nigeria Institute of Medical Research (NIMR), Yaba, Lagos, Nigeria, tundesalako{at}hotmail.com
↵* Equal contribution